In today’s recent session, 0.36 million shares of the Editas Medicine Inc (NASDAQ:EDIT) have been traded, and its beta is 2.02. Most recently the company’s share price was $5.81, and it changed around $0.2 or 3.57% from the last close, which brings the market valuation of the company to $477.81M. EDIT at last check was trading at a discount to its 52-week high of $11.69, offering almost -101.2% off that amount. The share price’s 52-week low was $4.45, which indicates that the recent value has risen by an impressive 23.41% since then. We note from Editas Medicine Inc’s average daily trading volume that its 3-month average coming to 2.11 million.
Editas Medicine Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.22. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended EDIT as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Editas Medicine Inc is expected to report earnings per share of -0.7 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Editas Medicine Inc (NASDAQ:EDIT) trade information
Instantly EDIT has been showing a green trend so far today with a performance of 3.57% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -42.65% year-to-date, but still up 18.33% over the last five days. On the other hand, Editas Medicine Inc (NASDAQ:EDIT) is 5.83% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $19.5, which translates to bulls needing to increase their stock price by 70.21% from its current value. Analyst projections state that EDIT is forecast to be at a low of $7 and a high of $44.
Editas Medicine Inc (EDIT) estimates and forecasts
Editas Medicine Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -35.94 percent over the past six months and at a -33.66% annual growth rate that is well below the industry average of 15.50%. The year-over-year growth rate is expected to be -58.80%, down from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 5.08M in revenue for the current quarter. 12 analysts expect Editas Medicine Inc to make 5.47M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 4.17M and 5.34M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 21.80%. Forecasts for the next quarter put sales growth at 2.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 2.88%. Editas Medicine Inc earnings are expected to increase by -32.48% in 2024, but the outlook is positive 1.70% per year for the next five years.
EDIT Dividends
Editas Medicine Inc’s next quarterly earnings report is expected to be released in August.
Editas Medicine Inc (NASDAQ:EDIT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.35% of Editas Medicine Inc shares, and 80.69% of them are in the hands of institutional investors. The stock currently has a share float of 80.97%. Editas Medicine Inc stock is held by 309 institutions, with State Street Corporation being the largest institutional investor. By Mar 31, 2024, it held 10.65% of the shares, which is about 8.76 shares worth $50.77 million.
Vanguard Group Inc, with 10.40% or 8.56 shares worth $49.58 million as of Mar 31, 2024, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of May 31, 2024. The former held 6.49 shares worth $37.62 million, making up 7.89% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.57 shares worth around $14.88 million, which represents about 3.12% of the total shares outstanding.
